Group sequential trials revisited: Simple implementation using SAS

The methodology of group sequential trials is now well established and widely implemented. The benefits of the group sequential approach are generally acknowledged, and its use, when applied properly, is accepted by researchers and regulators. This article describes how a wide range of group sequential designs can easily be implemented using two accessible SAS functions. One of these, PROBBNRM is a standard function, while the other, SEQ, is part of the interactive matrix language of SAS, PROC IML. The account focuses on the essentials of the approach and reveals how straightforward it can be. The design of studies is described, including their evaluation in terms of the distribution of final sample size. The conduct of the interim analyses is discussed, with emphasis on the consequences of inevitable departures from the planned schedule of information accrual. The computations required for the final analysis, allowing for the sequential design, are closely related to those conducted at the design stage. Illustrative examples are given and listings of suitable of SAS code are provided.

[1]  H Merabet,et al.  The design and analysis of sequential clinical trials , 2013 .

[2]  Christopher Jennison,et al.  Statistical Approaches to Interim Monitoring of Medical Trials: A Review and Commentary , 1990 .

[3]  P. O'Brien,et al.  A multiple testing procedure for clinical trials. , 1979, Biometrics.

[4]  A. Wade,et al.  Adaptive Design Methods in Clinical Trials , 2007 .

[5]  John Whitehead,et al.  Incorporating Data Received after a Sequential Trial Has Stopped into the Final Analysis: Implementation and Comparison of Methods , 2003, Biometrics.

[6]  John Whitehead,et al.  Evaluation of a sequential global test of improved recovery following stroke as applied to the ICTUS trial of citicoline , 2009, Pharmaceutical statistics.

[7]  John Whitehead,et al.  The double triangular test in practice , 2004 .

[8]  W. J. Hall,et al.  Sequential tests and estimates after overrunning based on p-value combination , 2008, 0805.3070.

[9]  W J Shih,et al.  Modifying the design of ongoing trials without unblinding. , 1998, Statistics in medicine.

[10]  P. Armitage,et al.  Sequential medical trials. 2nd edition. , 1975 .

[11]  William J. Hall,et al.  Sequential tests and estimators after overrunning based on maximum‐likelihood ordering , 2002 .

[12]  Meinhard Kieser,et al.  On the inappropriateness of an EM algorithm based procedure for blinded sample size re‐estimation , 2002, Statistics in medicine.

[13]  K K Lan,et al.  The B-value: a tool for monitoring data. , 1988, Biometrics.

[14]  W. Lehmacher,et al.  Adaptive Sample Size Calculations in Group Sequential Trials , 1999, Biometrics.

[15]  S. Pocock,et al.  Trials stopped early: too good to be true? , 1999, The Lancet.

[16]  Christopher Jennison,et al.  Interim analyses: the repeated confidence interval approach , 1989 .

[17]  B. Turnbull,et al.  Group Sequential Methods with Applications to Clinical Trials , 1999 .

[18]  B. Clarke,et al.  Pushing the Limits of Contemporary Statistics: Contributions in Honor of Jayanta K. Ghosh , 2008, 0806.4445.

[19]  R. Madsen,et al.  P values for tests using a repeated significance test design , 1982 .

[20]  A. Gould.  Planning and revising the sample size for a trial. , 1995, Statistics in Medicine.

[21]  A Whitehead,et al.  Mid-trial design reviews for sequential clinical trials. , 2001, Statistics in medicine.

[22]  P. Bauer,et al.  Evaluation of experiments with adaptive interim analyses. , 1994, Biometrics.

[23]  J. Whitehead,et al.  Overrunning and underrunning in sequential clinical trials. , 1992, Controlled clinical trials.

[24]  S. Pocock.  Group sequential methods in the design and analysis of clinical trials , 1977 .

[25]  J. S. D. Cani,et al.  Group sequential designs using a family of type I error probability spending functions. , 1990, Statistics in medicine.